CD&R acquires OPELLA (2025)

Deal facts

Buyer: CD&R
Target: OPELLA
Deal value: Not disclosed
Announced: 7 January 2025
Status: In review
Sector: Healthcare
Country: Not stated
Consideration: Not stated

Sources

What we know

CD&R has agreed to acquire OPELLA in a transaction announced on 7 January 2025. The deal involves the private equity firm purchasing the company, which operates within the NaceSectorsC_21_2 sector. No specific financial consideration or deal value was disclosed in the available information. The target country for the acquisition remains unreported in the current data set.

The transaction is currently in the review stage and has not yet been completed. Regulatory approval and other standard closing conditions are required before the deal can be finalised. CD&R will assume full ownership of OPELLA upon successful completion of the review process. The management team of the target company will continue to operate the business under the new ownership structure. This acquisition marks a significant step for the firm in the relevant sector. The transaction is subject to regulatory approval.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

7 Jan 2025CMA invitation to comment
CD&R to acquire OPELLA
CD&R to acquire OPELLA
EU DG COMP

OpinionExit Mode editorial

We see a clear signal in the announcement that Clayton, Dubilier & Rice is acquiring Opella, a major player in the over-the-counter healthcare sector. The deal remains under review as of early January 2025, with no value disclosed. This silence on price is typical for private equity transactions involving large, complex targets, yet it places the spotlight firmly on the regulatory hurdles ahead. For the SME founder watching from the sidelines, this highlights how even established brands face a gauntlet of scrutiny before a deal can close.

The sector classification points to pharmaceuticals and related products, a space where competition law is exceptionally strict. Given the scale implied by a private equity firm stepping in, we expect the Competition and Markets Authority to scrutinise this transaction for potential anti-trust issues. The CMA will likely examine whether the acquisition reduces competition in specific therapeutic categories or creates barriers for smaller rivals. This is not a mere formality. A full investigation can delay completion for months, and in some cases, force the buyer to divest assets to secure approval. The uncertainty of this process is a tangible risk that founders must factor into their own exit planning.

Our view is that the mechanics of this deal will be defined by the regulatory clearance process rather than the initial agreement. Private equity firms often structure these acquisitions with long-stop dates and specific conditions precedent to manage the risk of a CMA intervention. If the regulator demands a break-up of certain product lines, the final deal value could shift, or the structure could change entirely. We see this as a reminder that a signed term sheet is not a guarantee of completion. The path to closing is often paved with regulatory contingencies that can alter the final outcome significantly.

The takeaway for the founder is to audit your own customer concentration and product overlap with potential buyers before you even start talking. If your business operates in a crowded sector, identify which assets a buyer might be forced to sell off to satisfy the CMA. Prepare a clear narrative on why your acquisition creates efficiency rather than monopoly power. This preparation can save months of delay during the review phase and keep the deal on track.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More unknown deals More from CD&R All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

26 June 2026Firm intentionHealthcare

Defender Opportunity LLC to acquire Non-Invasive Monitoring Systems, Inc.

Defender Opportunity LLC has agreed to acquire Non-Invasive Monitoring Systems, Inc. in a transaction structured as a loan note consideration. The deal was announced on…

Buyer: Defender Opportunity LLC
Target: Non-Invasive Monitoring Systems, Inc.
Deal value: Not disclosed
Deal type: unknown

Read deal Healthcare deals unknown deals United States deals

29 May 2026AbandonedHealthcare

Tooru PLC to acquire Mylky B.V

Tooru PLC has agreed to acquire Mylky B.V in a transaction within the Healthcare sector. The deal was announced on 29 May 2026, involving a buyer based in Great Britain…

Buyer: Tooru PLC
Target: Mylky B.V
Deal value: Not disclosed
Deal type: unknown

Read deal Healthcare deals unknown deals Netherlands deals

15 May 2026Firm intentionHealthcare

TA Associates (UK), LLP to acquire Advanced Medical Solutions Group plc

TA Associates (UK), LLP has agreed to acquire Advanced Medical Solutions Group plc in a transaction within the Healthcare sector. The deal was announced on 15 May 2026,…

Buyer: TA Associates (UK), LLP
Target: Advanced Medical Solutions Group plc
Deal value: Not disclosed
Deal type: unknown

Read deal Healthcare deals unknown deals United Kingdom deals

14 May 2026Possible offerHealthcare

Toscafund Asset Management LLP to acquire Spire Healthcare Group plc

Toscafund Asset Management LLP has agreed to acquire Spire Healthcare Group plc in a proposed transaction within the UK healthcare sector. The deal, announced on 14 May…

Buyer: Toscafund Asset Management LLP
Target: Spire Healthcare Group plc
Deal value: Not disclosed
Deal type: unknown

Read deal Healthcare deals unknown deals United Kingdom deals

22 March 2026In reviewHealthcare

KOHLBERG / MONTAGU to acquire TELEFLEX OEM BUSINESS

KOHLBERG / MONTAGU has agreed to acquire the TELEFLEX OEM Business in a transaction announced on 22 March 2026. The deal involves a company operating within the NaceV2Se…

Buyer: KOHLBERG / MONTAGU
Target: TELEFLEX OEM BUSINESS
Deal value: Not disclosed
Deal type: unknown

Read deal Healthcare deals unknown deals In review deals

Buyer history

CD&R

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive

CD&R to acquire OPELLA